Animal models of arthritis are used to evaluate potential antiarthritis drugs for clinical use. Therefore capacity of the model to predict efficacy in human disease is one of the most important criteria in model selection. Animal models of rheumatoid arthritis (RA) with a proven track record of predictability include rat adjuvant arthritis, rat type II collagen arthritis, mouse type II collagen arthritis, and antigen-induced arthritis in several species. Agents currently in clinical use (or trials) that are active in these models include corticosteroids, methotrexate, nonsteroidal anti-inflammatory drugs, cyclosporin A, leflunomide, interleukin-1 receptor antagonist, and soluble tumor necrosis factor receptors. For some of these agents, the models also predict that toxicities seen at higher doses for prolonged periods would preclude dosing in humans at levels that might provide disease-modifying effects. Animal models of osteoarthritis (OA) include mouse and guinea pig spontaneous OA, meniscectomy and ligament transection in guinea pigs, meniscectomy in rabbits, and meniscectomy and cruciate transection in dogs. None of these models have a proven track record of predictability in human disease because there are no agents that have been proven to provide anything other than symptomatic relief in human OA. Efficacy data and features of the various models of RA and OA are discussed with emphasis on their proven relevence to human disease.
Bendele AM (1987). Progressive chronic osteoarthritis in femorotibial joints of partial medial meniscectomized guinea pigs. Vet. Pathol.24: 444-448.
2.
Bendele AM, Aitchison R., McAbee T., Sennello G., Frazier J., Chlipala L., and McCabe D. (1998). Sustained blood levels of IL-1ra improve efficacy in animal models of arthritis: Comparison of efficacy in animal models to human clinical data. Arthritis Rheum. (in press).
3.
Bendele AM, Bendele RA, Hulman JF, and Swann BP (1996). Beneficial effects of diacetylrhein treatment in guinea pigs with spontaneous osteoarthritis. Rev. Pract. Suppl. 6: 35-39.
4.
Bendele AM and Hulman JF (1988). Spontaneous cartilage degeneration in guinea pigs . Arthritis Rheum.31: 561-565.
5.
Bendele AM and Hulman JF (1991). Effects of body weight restriction on the development and progression of spontaneous OA in guinea pigs. Arthitis Rheum. 34: 1180-1184.
6.
Bendele AM, McComb J., Gould T., Chlipala L., Frazier J., Colagiovanni D., and Edwards C. (1998). Comparative efficacy of sTNF-RI, a novel monomeric recombinant soluble TNF type I receptor, to dimeric sTNF-RI and sTNF-RII IgG1 Fc fusion proteins in animal models of rheumatoid arthritis. Proc. Int. TNF Congr. 7. May, 1998, in Hyannis , Massachusetts.
7.
Bendele AM and White SL (1987). Early histopathologic and ultrastructural alterations in femorotibial joints of partial medial meniscectomized guinea pigs. Vet. Pathol.24: 436-443.
8.
Bendele AM, White SL, and Hulman JF (1989). Osteoarthritis in guinea pigs: Histopathologic and scanning electron microscopic features. Lab. Anim. Sci.39: 115-1211.
9.
Bendele AM, White SL, Hulman JF, and Bean JS (1991). Osteoarthritis, model No. 379. In: Handbook: Animal Models of Human Disease, fasc. 18, CC Capen, TC Jones, and G Migaki (eds). Registry of ComparativePathology, Washington, D.C., pp. 3-6.
10.
Benslay DN and Bendele AM (1991). Development of a rapid screen for detecting and differentiating immunomodulatory vs. anti-inflammatory compounds in rats. Agents Actions34: 254-256.
11.
Brackertz D. , Mitchell GF, and Mackay IR (1977). Antigen-induced arthritis in mice. I. Induction of arthritis in various strains of mice. Arthritis Rheum.20: 841-850.
12.
Bresnihan B. (1996). Treatment with recombinant human interleukin-1 receptor antagonist in rheumatoid arthritis. Results of a randomized double blind placebo controlled multicenter trial. Arthritis Rheum.39: S73 (abstract).
13.
Brooks PM and Day RO (1991). Nonsteroidal anti-inflammatory drugs—Differences and similarities. N. Engl. J. Med.324: 1716-1722.
14.
Butler RC, Davie Mwj, Worsfold M., and Sharp CA (1991). Bone mineral content in patients with rheumatoid arthritis: Relationship to low-dose steroid therapy. Br. J. Rheumatol. 30: 86-90.
15.
Campion GV, Lebsack ME, Lookabaugh J., Gordon J., and Catalano M. (1996). Dose range and dose frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1ra arthritis study group. Arthritis Rheum.88: 1092-1101.
16.
Carlson RP, Datko LJ, O'Neil-Davis L., Blazek EM, Delustro F., Beideman R., and Lewis AJ (1985). Comparison of inflammatory changes in established type II collagen and adjuvant induced arthritis using outbred Wistar rats . Int. J. Immunopharmacol.7: 811-826.
17.
Dougados M. , Nguyen M., Berdah L., Lequesne M., Mazieres B., and Vignon E. (1994). Evaluation of the chondromodulating effect of diacerhein in hip osteoarthritis . Osteoarthritis Cartilage2: 19 (B9).
18.
Drosos AA, Tsifetaki N., Tsiakou EK, Timpanidou M., Tsampoulas C., Tatsis CK, Kotoulas K., and Moutsopoulos HM (1997). Influence of methotrexate on radiographic progression in rheumatoid arthritis: A sixty-month prospective study. Clin. Exp. Rheumatol.15: 263-267.
19.
Hunneyball IM, Crossley MJ, and Spowage M. (1986). Pharmacological studies of antigen-induced arthritis in BALB/c mice. I. Characterization of the arthritis and the effects of steroidal and nonsteroidal anti-inflammatory agents. Agents Actions18: 384-393.
20.
Hunneyball IM, Crossley MJ, and Spowage M. (1986). Pharmacological studies of antigen-induced arthritis in BALB/c mice. II. The effects of second-line anti-rheumatic drugs and cytotoxic agents on histopathological changesAgents Actions18: 394-400.
21.
Meisel AD and Bullough PG (1984). Osteoarthritis of the knee. In: Atlas of Osteoarthritis, AD Meisel and PG Bullough (eds). Lea and Febiger, Philadelphia, pp. 2.1-2.25, 5.1-5.19.
22.
Moreland LW , Margolies G., Heck LW, Saway A., Blosch C., Hanna R., and Koopman WJ (1996). Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: Toxicity and dose finding trial in refractory rheumatoid arthritis. J. Rheumatol.23: 1845-1848.
23.
Moreland LW , Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettinger RE, Cohen S., Koopman WJ, Mohlen K., Widmer MB, and Blosch CM (1997). Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med.337: 141-147.
24.
Nordling C. , Karlsson-Parra A., Jansson L., Holmdahl R., and Klareskog L. (1992). Characterization of a spontaneously occurring arthritis in male DBA/1 mice . Arthritis Rheum.35: 717-722.
25.
Pearson CM (1956). Development of arthritis, periarthritis and periostitis in rats given adjuvants. Proc. Soc. Exp. Biol. Med.91: 95-100.
26.
Seitz M., Loetscher P., Dewald B., Towbin H., Rordorf C., Gallati H., and Gerber NJ (1996). Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1B and IL—8—Markers of remission in rheumatoid arthritis during treatment with methotrexate. J. Rheumatol.23: 1512-1516.
27.
Sokoloff L. , Crittenden LB, Yamamoto RS, and Jay GE (1962). The genetics of degenerative joint disease in mice. Arthritis Rheum.5: 531-546.
28.
Terato K., Hashida R., Miyamoto K., Morimoto T., Kata Y., Kobayashi S., Tajima T., Otake S., Horni H., and Nagai Y. (1982). Histological, immunological, and biochemical studies on type II collagen arthritis in rats. Biomed. Res.3: 495-523.
29.
Trentham DE , Townes AS, and Kang AH (1977). Autoimmunity to type II collagen: An experimental model of arthritis. J. Exp. Med.146: 857-868.
30.
Wooley PH, Whalen JD, Chapman DL, Berger AE, Richard KA, Aspar DG, and Staite ND (1993). The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum.36: 1305-1314.
